Biosurgery Market Analysis

The Middle East and Africa biosurgery market is driven by the region's expanding healthcare infrastructure, rising surgical volumes, and increasing adoption of advanced surgical technologies. Rapid population growth, alongside increasing prevalence of chronic diseases including cardiovascular disorders, diabetes, and obesity, continues to expand demand for biosurgical products such as hemostatic agents, surgical sealants, bone-graft substitutes, and adhesion barriers. Clinical adoption is supported by government healthcare transformation initiatives, growing medical tourism, and the gradual adoption of minimally invasive surgical techniques, strengthening the region's position as an emerging market for surgical biomaterials. According to the research report, "Middle East & Africa Biosurgery Market Outlook, 2031," published by Actual Market Research, the Middle East & Africa Biosurgery Market is anticipated to grow at more than 6.98% CAGR from 2026 to 2031.. Across the Middle East, healthcare expenditure varies significantly by country, with GCC nations leading in healthcare investment. In the UAE, health spending is estimated at 5.4% of GDP in 2025, according to MOHAP figures. Saudi Arabia allocates substantial resources to healthcare, with total health expenditure exceeding SAR 175 billion annually, representing approximately 6% to 7% of GDP. In South Africa, health spending reached 9.14% of GDP in 2025, ranking 40th globally and representing the highest on record. However, across Sub-Saharan Africa, governments spend on average only 2% of GDP on health less than half the aspirational target of 5% and far below regions like North America (9%) and Europe and Central Asia (7%). These statistics highlight a diverse healthcare landscape across the Middle East and Africa, supporting growing surgical volumes and driving demand for biosurgical products across all major surgical specialties. Saudi Arabia dominates the Middle East biosurgery market owing to its large population, significant healthcare investment under Vision 2030, and expanding surgical capacity.

Healthcare providers in the Kingdom set a new record by conducting more than 11,300 surgeries in a single week in 2025. The UAE supports steady demand through its advanced healthcare infrastructure and position as a premier medical tourism destination, with Dubai welcoming over 691,000 international health tourists in 2023. South Africa represents the largest biosurgery market in Sub-Saharan Africa, supported by its dual public-private healthcare system and the most sophisticated medical infrastructure on the continent. Across the region, the biosurgery market continues to benefit from technological innovation, including robotic-assisted surgery, advanced hemostatic agents, and synthetic sealants. The Middle East minimally invasive surgery market was valued at approximately USD 7.37–7.80 billion in 2025 and is expected to reach USD 13.41 billion by 2033, growing at a CAGR of 7.02%. Saudi Arabia dominated the Middle East and Africa minimally invasive surgery market with a revenue share of 37.5% in 2025. Saudi Arabia is expected to retain market leadership, while the UAE and South Africa are projected to support future regional expansion through strengthening healthcare infrastructure, increasing awareness, and broader access to advanced biosurgical products. .

Market Dynamic

BiosurgerySegmentation

Surgical Sealants and Adhesives is the fastest-growing product segment because increasing adoption of robotic-assisted and minimally invasive surgical techniques across Middle Eastern healthcare systems creates demand for advanced tissue-sealing solutions that can be delivered through small incisions.

Surgical Sealants and Adhesives represent the fastest-growing product category in the Middle East and Africa biosurgery market, driven by the region's accelerating adoption of robotic-assisted and minimally invasive surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. Saudi Arabia's healthcare providers performed more than 11,300 surgeries in a single week in 2025, with robotic systems being introduced for thoracic surgery, urology, and gynecological oncology. The Middle East minimally invasive surgery market is expected to grow at a CAGR of 7.02% from 2025 to 2033. This shift toward advanced surgical platforms creates new opportunities for surgical sealants and adhesives that can be delivered through small incisions. The growing demand for advanced surgical technologies supports the expansion of this segment. The UAE leads in the adoption of these advanced sealant technologies in the region, supported by its position as a premier medical tourism destination and advanced healthcare infrastructure.

Cardiovascular Surgery is the fastest-growing application segment because rising cardiovascular disease prevalence, aging populations, and technological advancements in cardiac procedures are increasing demand for vascular sealants, hemostatic agents, and soft-tissue attachments.

Cardiovascular Surgery represents the fastest-growing application area in the Middle East and Africa biosurgery market, driven by the high prevalence of cardiovascular disease and the growing burden of non-communicable diseases. In the UAE, the Ministry of Health and Prevention has performed robotic cardiac surgeries and catheterization procedures. Saudi Arabia's King Faisal Specialist Hospital performed the world's first fully robotic heart transplant. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures, including coronary artery bypass grafting, valve replacements, and vascular reconstructions. The growing adoption of minimally invasive cardiac surgery techniques is creating new opportunities for advanced biosurgical products designed for smaller incisions and precision delivery. Saudi Arabia and the UAE, with their advanced cardiac surgical infrastructure and significant healthcare investment, lead the adoption of biosurgical products in cardiovascular applications in the region.

Synthetic and Semi-Synthetic products are the fastest-growing source category because cost-effectiveness, consistent quality, and lower immunogenicity risks support adoption across price-sensitive healthcare markets in the Middle East and Africa.

Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Middle East and Africa biosurgery market, driven by cost-effectiveness, consistent quality, and lower immunogenicity risks. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The growing emphasis on cost-containment in healthcare systems, particularly in Africa where governments spend on average only 2% of GDP on health, favors synthetic alternatives for certain applications. In South Africa, with health spending per capita at only $573 in 2025, price sensitivity drives demand for cost-effective synthetic products. In the UAE, the "Medical Devices Regulation, Cabinet Resolution No. 32 of 2023" mandates biocompatibility standards, supporting the adoption of high-quality synthetic alternatives. The emphasis on cost-effectiveness in healthcare systems, combined with consistent quality and reduced immunogenicity risks, supports the growing adoption of synthetic alternatives across Middle Eastern and African healthcare facilities.

Ambulatory Surgical Centers are the fastest-growing end-user segment because the shift toward outpatient and same-day discharge models, cost-efficiency, and technological advancements are increasing procedure volumes in ASC settings across the Middle East and Africa.

Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Middle East and Africa biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. The expansion of outpatient surgical capacity, supported by private healthcare investment and medical tourism, supports the adoption of biosurgical products in these settings. In the UAE, Burjeel Holdings performed 22,930 surgeries in Q2 2025. Technological advances enabling more complex procedures to be performed safely in outpatient settings, patient preference for convenience, and payer initiatives to reduce healthcare expenditure are driving ASC growth. For biosurgery manufacturers, this trend requires adaptation of product portfolios developing formulations and delivery systems optimized for the fast-paced, high-throughput ASC environment and adjustment of commercial strategies to target the growing ASC customer base. The UAE leads in ASC-based biosurgical product adoption in the region, supported by its position as a premier medical tourism destination and advanced private healthcare infrastructure.

Biosurgery Market Regional Insights

Saudi Arabia dominates the Middle East biosurgery market because advanced healthcare infrastructure, government investment under Vision 2030, and high surgical procedure volumes support widespread biosurgical product utilization.

Saudi Arabia represents the largest contributor to the Middle East biosurgery market due to its advanced healthcare ecosystem, significant government investment, and large surgical volumes. Saudi Arabia allocates substantial resources to healthcare, with total health expenditure exceeding SAR 175 billion annually, representing approximately 6% to 7% of GDP. Healthcare providers in the Kingdom set a new record by conducting more than 11,300 surgeries in a single week in 2025. The country accounts for approximately 950,000 major surgical procedures annually across the GCC, representing roughly 50% of the GCC market. Saudi Arabia dominated the Middle East and Africa minimally invasive surgery market with a revenue share of 37.5% in 2025. The Kingdom has introduced robotic surgery at King Abdullah Medical City in Makkah, and King Faisal Specialist Hospital performed the world's first fully robotic heart and liver lobe transplants. Saudi Arabia is expected to retain its dominant position in the Middle East biosurgery market during the forecast period.
The UAE and South Africa provide significant growth opportunities because rising surgical procedure volumes, healthcare infrastructure expansion, and improving access to specialized surgical services are supporting biosurgery market development.

The UAE represents a rapidly growing biosurgery market supported by its position as a premier medical tourism destination and advanced healthcare infrastructure. Dubai welcomed over 691,000 international health tourists in 2023. The UAE ranks first globally in 10 healthcare competitiveness indicators in the IMD World Competitiveness Yearbook 2026. Healthcare expenditure reached an estimated 5.4% of GDP in 2025, with AED 5.745 billion allocated to healthcare and community prevention services. The UAE's medical devices market was valued at US$ 2.61 billion in 2024. Burjeel Holdings reported revenue of AED 25.8 billion for fiscal year 2024 and performed 22,930 surgeries in Q2 2025. The UAE's regulatory modernization, including the establishment of the Emirates Drug Establishment and the "Medical Devices Regulation, Cabinet Resolution No. 32 of 2023", supports continued market growth. South Africa represents the largest biosurgery market in Sub-Saharan Africa, supported by its dual public-private healthcare system and the most sophisticated medical infrastructure on the continent. South Africa's health spending reached 9.14% of GDP in 2025 the highest on record and ranking 40th globally. The country has over 470 public hospitals and over 260 private hospitals. South Africa's biosurgery market benefits from a focus on innovative surgical techniques and patient outcome improvement. However, adoption varies by province due to differences in healthcare budgets, specialist availability, and access to specialized surgical services. South Africa's health spending per capita of only $573 in 2025 reflects significant economic constraints that influence biosurgical product adoption.